Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Viridian Therapeutics, Inc. - Common Stock
(NQ:
VRDN
)
18.28
+0.06 (+0.33%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Viridian Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
September 02, 2026
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
August 06, 2026
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
June 26, 2026
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
May 27, 2026
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
May 06, 2026
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
May 05, 2026
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
May 05, 2026
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
May 05, 2026
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
March 30, 2026
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
February 26, 2026
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 08, 2026
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Prepares for Transformational 2026
January 06, 2026
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
December 22, 2025
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2025
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 07, 2025
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
November 05, 2025
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease
November 03, 2025
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock
October 21, 2025
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Proposed Underwritten Public Offering
October 21, 2025
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million
October 20, 2025
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2025
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates
September 15, 2025
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2025
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
August 06, 2025
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2025
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
July 30, 2025
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2025
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2025
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)
May 20, 2025
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
May 07, 2025
From
Viridian Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
